SCHEDULE: John Paul DeJoria Discloses 9.438% Stake in Telomir Pharma

John Paul DeJoria, through his family trust, has disclosed a 9.438% beneficial ownership stake in Telomir Pharmaceuticals, Inc.

Summary

• John Paul DeJoria, acting as trustee of the John Paul DeJoria Family Trust and in his individual capacity, beneficially owns 3,245,000 shares of Telomir Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.438% of the company's outstanding common stock.
• Mr. DeJoria holds sole voting power and sole dispositive power over all 3,245,000 shares.
• The filing indicates that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Telomir Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a prominent investor often indicates a belief in the company's underlying value, even without explicit performance data.

Positives

• A significant ownership stake by a high-profile investor like John Paul DeJoria can signal confidence in the company's long-term prospects and valuation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or operations.

Management Comments

• The certification states that, to the best of the reporting person's knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a substantial stake by a well-known investor like John Paul DeJoria in a pharmaceutical company such as Telomir Pharmaceuticals can be interpreted by the market as a vote of confidence, potentially attracting further investor interest in the sector or the company itself.

Stakeholder Impact

• Shareholders may view the significant stake by John Paul DeJoria as a positive indicator of the company's potential, potentially influencing market sentiment and share price.

Key Dates

Keywords

Telomir Pharmaceuticals, John Paul DeJoria, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Pharmaceuticals